Ally Bridge beefs up 'new generation' as investment firm passes 10-year mark
Ally Bridge Group, whose recent successes include CG Oncology‘s eye-popping IPO, said it promoted two people to head up its private equity strategies across biotech and medtech, and moved another employee up the ranks to lead its investing in the public markets.
Frank Yu, the firm’s chief executive and chief investment officer, said in an interview with Endpoints News that the moves represent the “new generation of Ally Bridge leadership.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
